Targeting HMGB2 acts as dual immunomodulator by bolstering CD8 <sup>+</sup> T cell function and inhibiting tumor growth in hepatocellular carcinoma
Wei‐Feng Qu(Ministry of Education of the People's Republic of China), Ying–Hong Shi(Ministry of Education of the People's Republic of China), Qianfu Zhao(Sun Yat-sen University), Xiaoling Wu(Fudan University), Gui‐Qi Zhu(Ministry of Education of the People's Republic of China), Yi Wang(Ministry of Education of the People's Republic of China), Jia Fan(Nanjing Tech University), Jian Zhou(Ministry of Education of the People's Republic of China), Zheng Tang(Ministry of Education of the People's Republic of China), Weiren Liu(Fudan University), Run Huang(Ministry of Education of the People's Republic of China), Yuan Fang(Ministry of Education of the People's Republic of China), Jun Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Meng‐Xin Tian(Sun Yat-sen University), Chen-Yang Tao(Fudan University), Xi‐Fei Jiang(Sun Yat-sen University), Jiafeng Chen(Ministry of Education of the People's Republic of China), Yichao Bu, Tian-Hao Chu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 11
Related Papers
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
|Nature|2019|982
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
|Liver Cancer|2020|828